Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks
Objectives: Ruxolitinib is used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease following allogeneic stem cell transplantation. This study aimed to determine the association between ruxolitinib and adverse events by evaluating case reports published betwee...
Saved in:
| Main Authors: | Hideyuki Tanaka, Mika Maezawa, Mizuki Tanaka, Ryogo Umetsu, Sakiko Hirofuji, Koumi Miyasaka, Satoshi Nakao, Yuka Nokura, Moe Yamashita, Nanaka Ichihara, Kana Sugishita, Tomofumi Yamazaki, Kohei Shiota, Hirofumi Tamaki, Kazuhiro Iguchi, Mitsuhiro Nakamura |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121251348420 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database
by: Kiyoka Matsumoto, et al.
Published: (2024-12-01) -
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01) -
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
by: Xiaohong Liu, et al.
Published: (2025-08-01) -
PREDICTORS OF RESPONSE TO RUXOLITINIB THERAPY IN PATIENTS WITH MYELOFIBROSIS
by: Irina Turtanova, et al.
Published: (2025-07-01) -
Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
by: O. G. Golovina, et al.
Published: (2024-11-01)